This is the authors' abstract. We don't add key points for this paper.
Colorectal cancer remains a leading cause of cancer-related mortality. Although KRAS G12C inhibitors have been approved for the treatment of multiple cancers, their clinical efficacy is often limited by KRAS reactivation. SOS1, a key guanine nucleotide exchange factor involved in KRAS activation and implicated in various malignancies, including colorectal and oral cancers, represents an attractive therapeutic target. In this study, fragment-based virtual screening targeting the Asn879 pocket of SOS1 was performed using the DrugBank database and an in-house chemical library, followed by structure-based optimization and structure–activity relationship analysis. Twenty derivatives were synthesized, among which compound 20, featuring a 6-methyl-1 H -imidazo[4,5-g]quinazoline scaffold, exhibited the most potent inhibition of the SOS1::KRAS G12C interaction (IC 50 = 4.11 nM). Compound 20 also demonstrated significant antiproliferative activity against DLD-1 CRC cells by inducing apoptosis and G0/G1 cell-cycle arrest. These results identify compound 20 as a promising lead for SOS1-targeted therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: